Strigolactone Analogs: Two New Potential Bioactiphores for Glioblastoma

Basit Öğe Kaydı
dc.authoridPrandi, Cristina/0000-0001-9510-8783
dc.authoridOzbil, Mehmet/0000-0002-1465-7674
dc.authoridSecen, Esma/0009-0002-6421-9776
dc.contributor.authorAntika, Gizem
dc.contributor.authorCinar, Zeynep Ozlem
dc.contributor.authorSecen, Esma
dc.contributor.authorOzbil, Mehmet
dc.contributor.authorTokay, Esra
dc.contributor.authorKockar, Feray
dc.contributor.authorPrandi, Cristina
dc.date.accessioned2025-01-27T20:31:28Z
dc.date.available2025-01-27T20:31:28Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractStrigolactones (SLs), carotenoid-derived phytohormones, control the plant response and signaling pathways for stressful conditions. In addition, they impact numerous cellular processes in mammalians and present new scaffolds for various biomedical applications. Recent studies demonstrated that SLs possess potent antitumor activity against several cancer cells. Herein, we sought to elucidate the inhibitory effects of SL analogs on the growth and survival of human brain tumor cell lines. Among four tested SLs, we showed for the first time that two lead bioactiphores, indanone-derived SL and EGO10, can inhibit cancer cell proliferation, induce apoptosis, and induce G1 cell cycle arrest at low concentrations. SL analogs were marked by increased expression of Bax/Caspase-3 genes and downregulation of Bcl-2. In silico studies were conducted to identify drug-likeness, blood-brain barrier penetrating properties, and molecular docking with Bcl-2 protein. Taken together, this study indicates that SLs may be promising antiglioma agents, presenting novel pharmacophores for further preclinical and clinical assessment.
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK) [218S814]; Canakkale Onsekiz Mart University [FHD-2021-3592]
dc.description.sponsorshipThis study was partially supported by The Scientific and Technological Research Council of Turkey (TUBITAK; Grant No. 218S814) and Canakkale Onsekiz Mart University (Scientific Research Projects, ID: FHD-2021-3592).
dc.identifier.doi10.1021/acschemneuro.1c00702
dc.identifier.endpage580
dc.identifier.issn1948-7193
dc.identifier.issue5
dc.identifier.pmid35138812
dc.identifier.scopus2-s2.0-85125037012
dc.identifier.scopusqualityQ1
dc.identifier.startpage572
dc.identifier.urihttps://doi.org/10.1021/acschemneuro.1c00702
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23162
dc.identifier.volume13
dc.identifier.wosWOS:000765068900004
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAmer Chemical Soc
dc.relation.ispartofAcs Chemical Neuroscience
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectGlioblastoma
dc.subjectSL analogs
dc.subjectantiproliferative
dc.subjectapoptotic effect
dc.subjectG1-phase arrest
dc.subjectantiglioma effect
dc.titleStrigolactone Analogs: Two New Potential Bioactiphores for Glioblastoma
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu